Constipation and Gut Transit in DMD Patients
Constipation and Gut Transit in Duchenne Muscular Dystrophy Patients
In this research study the investigators want to screen Duchenne Muscular Dystrophy (DMD) patients for signs and symptoms of constipation in patients over 18.
The investigators hypothesized:
- DMD patients have a high prevalence of constipation than in the general population.
- Prevalence of constipation will increase with age and with worsening functional status.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The following procedures will take place during the study.
Constipation Assessment:
- The patient will be asked to complete a questionnaire about any symptoms of constipation.
- A physician from the study team will perform an abdominal physical exam
- The patient will have routine x-rays that monitor for spine compression fractures. These films will also be used to assess stool content.
Clinical Information The following information will also be collected during the clinic visit ;
- Age at diagnosis and genetic mutation
- Age at loss of ambulation if applicable
- Medications
- Functional status
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with a diagnosis of Duchenne Muscular Dystrophy (based on clinical presentation and verified by compatible muscle biopsy or known dystrophin gene mutation).
- Age greater than or equal to 18 years old
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Motility
This arm will ingest the SmartPill.
|
The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GI transit times
Time Frame: up to 5 days
|
Gi transit times will be computed by an investigator.
|
up to 5 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Ajay Kaul, MD, Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013-1312
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.